

**General information about company**

Scrip code	544135
NSE Symbol	MUKKA
MSEI Symbol	NOTLISTED
ISIN	INE0CG401037
Name of the entity	Mukka Proteins Limited
Date of start of financial year	01-04-2023
Date of end of financial year	31-03-2024
Reporting Quarter	Yearly
Date of Report	31-03-2024
Risk management committee	Not Applicable
Market Capitalisation as per immediate previous Financial Year	Top 2000 listed entities

**Annexure I****Annexure I to be submitted by listed entity on quarterly basis****I. Composition of Board of Directors**

Disclosure of notes on composition of board of directors explanatory								Textual Information(1)
Whether the listed entity has a Regular Chairperson								Yes
Whether Chairperson is related to MD or CEO								No
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth
1	Mr	KALANDAN MOHAMMED HARIS	ABJPH9234P	03020471	Executive Director	Not Applicable	CEO-MD	19-01-1975
2	Mr	KALANDAN MOHAMMED ALTHAF	AGIPA6496J	03051103	Executive Director	Not Applicable		07-12-1979
3	Mr	KALANDAN MOHAMMAD ARIF	AVAPK6508Q	03020564	Executive Director	Not Applicable		15-01-1975
4	Mr	KALANDAN ABDUL RAZAK	ABTPR1412K	02530917	Non-Executive - Non Independent Director	Not Applicable		08-09-1943
5	Mrs	UMAIYYA BANU	ANGPB5823R	03051040	Non-Executive - Non Independent Director	Not Applicable		05-01-1958
6	Mr	KARKALA SHANKAR BALACHANDRA RAO	AAOPR8331H	03589394	Non-Executive - Independent Director	Chairperson		16-04-1954
7	Mr	HAMAD BAVA	ADGPB2259M	09448423	Non-Executive - Independent Director	Not Applicable		25-05-1952
8	Mr	NARENDRA SURENDRA KAMATH	ACGPK5266N	07255904	Non-Executive - Independent Director	Not Applicable		10-06-1965

**I. Composition of Board of Directors**

**Disqualification of Directors under section 164 of the Companies Act, 2013**

Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status
1	No				Active
2	No				Active
3	No				Active
4	No				Active
5	No				Active
6	No				Active
7	No				Active
8	No				Active

**I. Composition of Board of Directors**

Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA	20-01-2022	04-11-2010	20-01-2022		161	1	0	1	0			
2	NA	20-01-2022	04-11-2010	20-01-2022		161	1	0	1	0			
3	NA	20-01-2022	04-11-2010	20-01-2022		161	1	0	0	0			
4	No		22-02-2021			38	1	0	1	1			
5	NA		04-11-2010			161	1	0	0	0			
6	NA	15-01-2022	15-01-2022	15-01-2022		27	1	1	1	1			
7	NA	15-01-2022	15-01-2022	15-01-2022		27	1	1	1	0			
8	NA	15-01-2022	15-01-2022	15-01-2022		27	1	1	1	0			

**Text Block**

Textual Information(1)

The Company was listed on 7th March 2024 and accordingly, the provisions of Regulation 17(1A) of SEBI (LODR) Regulations, 2015 became applicable to the Company w.e.f. 7th March 2024. As a result, the Company is yet to pass a special resolution as required under Regulation 17(1A) in order to continue the directorship of Mr. Kalandan Abdul Razak as a non-executive director who has attained the age of 80 years. The requirements of Regulation 17(1A) shall be complied by the Company promptly.

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	03589394	KARKALA SHANKAR BALACHANDRA RAO	Non-Executive - Independent Director	Chairperson	17-01-2022		
2	09448423	HAMAD BAVA	Non-Executive - Independent Director	Member	17-01-2022		
3	03051103	KALANDAN MOHAMMED ALTHAF	Executive Director	Member	04-04-2020		

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	07255904	NARENDRA SURENDRA KAMATH	Non-Executive - Independent Director	Chairperson	17-01-2022		
2	09448423	HAMAD BAVA	Non-Executive - Independent Director	Member	17-01-2022		
3	02530917	KALANDAN ABDUL RAZAK	Non-Executive - Non Independent Director	Member	04-04-2020		

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	02530917	KALANDAN ABDUL RAZAK	Non-Executive - Non Independent Director	Chairperson	17-01-2022		
2	07255904	NARENDRA SURENDRA KAMATH	Non-Executive - Independent Director	Member	17-01-2022		
3	03020471	KALANDAN MOHAMMED HARIS	Executive Director	Member	17-01-2022		





Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	09448423	HAMAD BAVA	Non-Executive - Independent Director	Chairperson	17-01-2022		
2	03589394	KARKALA SHANKAR BALACHANDRA RAO	Non-Executive - Independent Director	Member	17-01-2022		
3	03020564	KALANDAN MOHAMMAD ARIF	Executive Director	Member	13-04-2017		

<b>Other Committee</b>						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks
1	03589394	KARKALA SHANKAR BALACHANDRA RAO	Initial Public Offering Committee	Non-Executive - Independent Director	Chairperson	
2	03020471	KALANDAN MOHAMMED HARIS	Initial Public Offering Committee	Executive Director	Member	
3	03051103	KALANDAN MOHAMMED ALTHAF	Initial Public Offering Committee	Executive Director	Member	

**Annexure 1****Annexure 1****III. Meeting of Board of Directors**

Disclosure of notes on meeting of board of directors explanatory							Textual Information(1)	No. of Independent Directors attending the meeting*
Sr	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	
1	23-12-2023				Yes	8		
2		05-02-2024	43		Yes	8	7	3
3		16-02-2024	10		Yes	8	6	2
4		24-02-2024	7		Yes	8	7	3
5		05-03-2024	9		Yes	8	7	3
6		06-03-2024	0		Yes	8	7	3
7		28-03-2024	21		Yes	8	7	3

**Text Block**

Textual Information(1)

The Board of Directors met twice on 16-02-2024. Since the report doesn't allow to fill the details of 2 Board Meetings held on the same day, the details of 2nd Board Meeting held on 16-02-2024 are detailed below:

Date of meeting: 16-02-2024

Maximum gap between any two consecutive (in number of days): 0 days

Whether requirement of Quorum met: Yes

Total Number of Directors as on date of the meeting: 8

Number of Directors present: 7

No. of Independent Directors attending the meeting\* : 3

**Annexure 1**

**IV. Meeting of Committees**

Disclosure of notes on meeting of committees explanatory							Textual Information(1)			
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	23-12-2023				Yes	3	3	2	2
2	Audit Committee	16-02-2024	54			Yes	3	3	2	2
3	Audit Committee	28-03-2024	40			Yes	3	3	2	4
4	Nomination and remuneration committee	28-03-2024				Yes	3	3	2	2
5	Stakeholders Relationship Committee	28-03-2024				Yes	3	3	1	2
6	Other Committee	28-02-2024		Initial Public Offering Committee		Yes	3	3	1	1

**Text Block**

Textual Information(1)

1. The Nomination and Remuneration Committee did not meet in the previous quarter.
2. The Stakeholders Relationship Committee did not meet in the previous quarter.
3. The Initial Public Offering Committee did not meet in the previous quarter.

**Annexure 1**

**V. Related Party Transactions**

Sr	Subject	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Whether prior approval of audit committee obtained	Yes	
2	Whether shareholder approval obtained for material RPT	NA	
3	Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes	



**Annexure 1****VI. Affirmations**

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	NA
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	No
9	Any comments/observations/advice of Board of Directors may be mentioned here:	Textual Information(1)

**Annexure 1**

Sr	Subject	Compliance status
1	Name of signatory	Kalandan Mohammed Haris
2	Designation	CEO

**Text Block**

Textual Information(1)

This being the first corporate governance report being filed by the Company, the filed report shall be placed before the Board in the next Board Meeting.

**Annexure II****Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)****I. Disclosure on website in terms of Listing Regulations**

Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
1	Details of business	Yes		<a href="https://www.mukkaproteins.com/">https://www.mukkaproteins.com/</a>
2	Terms and conditions of appointment of independent directors	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
3	Composition of various committees of board of directors	Yes		<a href="https://www.mukkaproteins.com/fish-meal-management.php">https://www.mukkaproteins.com/fish-meal-management.php</a>
4	Code of conduct of board of directors and senior management personnel	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
6	Criteria of making payments to non-executive directors	NA		
7	Policy on dealing with related party transactions	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
8	Policy for determining 'material' subsidiaries	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
9	Details of familiarization programmes imparted to independent directors	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
10	Email address for grievance redressal and other relevant details	Yes		<a href="https://www.mukkaproteins.com/investor-contact.php">https://www.mukkaproteins.com/investor-contact.php</a>
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		<a href="https://www.mukkaproteins.com/investor-contact.php">https://www.mukkaproteins.com/investor-contact.php</a>
12	Financial results	Yes		<a href="https://www.mukkaproteins.com/Finacials.php">https://www.mukkaproteins.com/Finacials.php</a>
13	Shareholding pattern	Yes		<a href="https://www.mukkaproteins.com/stock-exchange-disclosure.php">https://www.mukkaproteins.com/stock-exchange-disclosure.php</a>
14	Details of agreements entered into with the media companies and/or their associates	NA		

## Annexure II

**Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)**

### I. Disclosure on website in terms of Listing Regulations

Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address
15.1	Schedule of analyst or institutional investor meet and presentations made by the listed entity to analysts or institutional investors simultaneously with submission to stock exchange	NA		
15.2	Audio or video recordings and transcripts of post earnings/quarterly calls	NA		
16	New name and the old name of the listed entity	NA		
17	Advertisements as per regulation 47 (1)	Yes		<a href="https://www.mukkaproteins.com/stock-exchange-disclosure.php">https://www.mukkaproteins.com/stock-exchange-disclosure.php</a>
18	Credit rating or revision in credit rating obtained	Yes		<a href="https://www.mukkaproteins.com/newspaper-advertisement.php">https://www.mukkaproteins.com/newspaper-advertisement.php</a>
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes		<a href="https://www.mukkaproteins.com/Finacials.php">https://www.mukkaproteins.com/Finacials.php</a>
20	Secretarial Compliance Report	NA		
21	Materiality Policy as per Regulation 30 (4)	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes		<a href="https://www.mukkaproteins.com/investor-contact.php">https://www.mukkaproteins.com/investor-contact.php</a>
23	Disclosures under regulation 30(8)	Yes		<a href="https://www.mukkaproteins.com/stock-exchange-disclosure.php">https://www.mukkaproteins.com/stock-exchange-disclosure.php</a>
24	Statements of deviation(s) or variations(s) as specified in regulation 32	NA		
25	Dividend Distribution policy as per Regulation 43A(1)	Yes		<a href="https://www.mukkaproteins.com/policy.php">https://www.mukkaproteins.com/policy.php</a>
26	Annual return as provided under section 92 of the Companies Act, 2013	Yes		<a href="https://www.mukkaproteins.com/Investors-annual-return.php">https://www.mukkaproteins.com/Investors-annual-return.php</a>
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes		<a href="https://www.mukkaproteins.com/">https://www.mukkaproteins.com/</a>
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes		<a href="https://www.mukkaproteins.com/">https://www.mukkaproteins.com/</a>

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b) & 25(6)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	NA	
6	Plans for orderly succession for appointments	17(4)	NA	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	NA	
9	Minimum Information	17(7)	NA	
10	Compliance Certificate	17(8)	Yes	

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
11	Risk Assessment & Management	17(9)	NA	
12	Performance Evaluation of Independent Directors	17(10)	Yes	
13	Recommendation of Board	17(11)	NA	
14	Maximum number of Directorships	17A	Yes	
15	Composition of Audit Committee	18(1)	Yes	
16	Meeting of Audit Committee	18(2)	Yes	
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes	
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes	
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes	
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes	

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	NA	
26	Meeting of Risk Management Committee	21(3A)	NA	
27	Quorum of Risk Management Committee meeting	21(3B)	NA	
28	Gap between the meetings of the Risk Management Committee	21(3C)	NA	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	



**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	NA	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	NA	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	Yes	
36	Alternate Director to Independent Director	25(1)	NA	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

**Annexure II****II. Annual Affirmations**

Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	NA	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	NA	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Disclosure of Shareholding by Non-Executive Directors	26(4)	Yes	
47	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
48	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA	
49	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2)	NA	
	Any other information to be provided		Textual Information(1)	

**Text Block**

Textual Information(1)

The Company got listed on 07-03-2024, therefore the points those have been marked as Not Applicable shall be complied by the Company within the first quarter of FY 2024-25 to the extent applicable.

**Annexure II**

1	Name of signatory	Kalandan Mohammed Haris
2	Designation	CEO

**Annexure II**

**III. Affirmations**

<b>Sr</b>	<b>Particulars</b>	<b>Compliance status (Yes/No/NA)</b>
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes
	Any other information to be provided	

**Annexure II**

1	Name of signatory	Kalandan Mohammed Haris
2	Designation	CEO

<b>Additional Half yearly Disclosure</b>		
Applicability of disclosure	Not Applicable	
Reason for Non Applicability	Textual Information(1)	

<b>Text Block</b>	
Textual Information(1)	Not Applicable



<b>Details of Cyber security incidence</b>		
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter		No
Number of cyber security incidence or breaches or loss of data event occurred during the quarter		
Sr.	Date of the event	Brief details of the event

**Signatory Details**

Name of signatory	Kalandan Mohammed Haris
Designation of person	CEO
Place	Mangalore
Date	20-04-2024

